- HCC Panel patent application (PCT/US2017/018040 and Taiwan 106106107)
o One of two most important Glycotest patent families—protects Glycotest HCC Panel test o Fresh application providing protection to 2037, including in China
- PCT/US2010/044307
o Second of two most important Glycotest patent families—protects engineered lectins for fucosylated biomarker assays o Issued European (2462240) and Chinese (ZL201080044720.8) patents o Protection to 2030, including in China
- PCT/US2006/017478
o Methods for diagnosing liver disease using fucosylated biomarkers o Issued US (7,776,550; 8,183,000; 10,082,512), Australian (2006244398; 2012247075; 2015275300), Japanese (5964769;
6184935) and Canadian (2607285) patents and allowed European and Japanese patents o Protection to 2026
- US2009/0253180
o Methods for diagnosing liver disease using fucosylated LRAGG o Issued US patents (9,110,078; 10,180,436) o Protection to 2028
- Trade Secrets
o Fucosylated biomarker assay manufacturing technology o Fucosylated biomarker assay methods